

Wellnex Life Entitlement Offer Open & Prospectus Dispatched

Highlights:

- Entitlement Offer to raise up to \$13.6 million opens today.
- Pro-rata non-renounceable 1:1 Entitlement Offer to Eligible Shareholders together with 1 attaching option for every 3 Entitlement Shares issued.
- Funds raised will be used to fund the acquisition of Pain Away and pay for the costs in connection with the Entitlement Offer and the Pain Away transaction.
- Eligible shareholders can request an electronic copy of their personalised [Entitlement Offer Form](#) here.
- Wellnex CEO - George Karafotias and Managing Director - Zack Bozinovski will be holding a live shareholder briefing today, Friday 17 November at 12.00pm (AEDT). [Register here.](#)

Wellnex Life Limited (Wellnex, WNX or Company) (ASX:W NX), owner and developer of some of Australia's leading health brands, announces that its pro-rata non-renounceable entitlement offer of new fully paid ordinary shares (**Shares**) to raise up to \$13.6 million (before costs) opens today.

The Offer entitles eligible shareholders to subscribe for 1 new Entitlement Share (at an issue price of \$0.028) for every 1 share held on the record date of 7.00pm (AEDT) on Thursday, 16 November 2023, together with 1 attaching option (exercisable at \$0.05 and expiring 30 June 2025) for every 3 Entitlement Shares issued (**Entitlement Offer**).

The Entitlement Offer is being made pursuant to a prospectus, a copy of which was lodged with ASIC and ASX, and made available on the Company's website, on 13 November 2023 (**Prospectus**).

The Funds raised will be used to fund the acquisition of Pain Away and pay for the costs in connection with the Entitlement Offer and the Pain Away transaction.

The Entitlement Offer opened today, Friday, 17 November 2023, and will close at 5.00pm (AEDT) on Tuesday, 28 November 2023 (unless extended).

Dispatch of documents

Wellnex confirm that the following documents were dispatched today:

- For all eligible shareholders who have nominated to receive documents from Wellnex electronically, an email providing access to the Prospectus and personalised entitlement and acceptance form by electronic means;

- For all other eligible shareholders, a letter via post notifying them of the Entitlement Offer and providing instructions on how to access the Prospectus and their personalised entitlement and acceptable form online; and
- For all ineligible retail shareholders, a letter notifying them of the Entitlement offer and their ineligibility to participate in the Entitlement Offer.

Target Market Determination

The Company has prepared a target market determination in respect of the Options offered under the Entitlement Offer and Shortfall Offer, which is available on the Company's website: <https://wellnexlife.investorportal.com.au/entitlement-offer/>

Participate in the Entitlement Offer

Eligible Shareholders can request an electronic copy of their personalised Entitlement Offer application form from the link below:

<https://wellnexlife.investorportal.com.au/request-form/>

Should you wish to apply for an amount greater than your allocation, use the same BPAY details to fund the full amount you would like to be allocated.

Reach Markets are assisting with the management of the Entitlement Offer and can be contacted as follows:

By phone: +61 (3) 8080 5975

By email: investors@reachmarkets.com.au

Shareholder Briefing

A live and online shareholder briefing will take place via webinar on Friday, 17 November 2023 at 12.00pm (AEDT) and Tuesday, 21 November at 1.00pm (AEDT).

[Register for the webinar here.](#)

Following registration, you will receive a calendar invite with the details to join the online briefing.

This ASX announcement has been authorised by the Board of Wellnex Life Limited.

For further information, please contact:

Reach Markets

P: +61 3 8080 5975

E: investors@reachmarkets.com.au

Wellnex Life Limited

Building 2, Level 3, Suite 69, 574 Plummer Street, Port Melbourne VIC Australia
info@wellnexlife.com.au Phone: +61 3 8399 9419

About Wellnex Life

Wellnex Life Limited (ASX: WNX) is a consumer healthcare business with a track record for developing, licensing, and marketing registered products and brands to customers in the growing healthcare market segment. Since listing in 2021, Wellnex Life has successfully launched a host of brands and products now ranged in major retailers in the healthcare market space, pharmacies and supermarkets included. Its distribution arrangements have seen Wellnex Life secure significant licensing arrangements with major pharmaceutical companies in Australia and globally that have given the company's registered products a distribution channel with a steadily increasing global geographic footprint.

Wellnex Life has more recently agreed to acquire leading Australian topical pain relief brand Pain Away. Its addition to Wellnex Life's product offering both compliments and accelerates the potential growth of the company's business operations. This transformational acquisition gives added impetus to Wellnex Life's financial growth and scale and reinforces its place as a major and respected participant in the growing healthcare market, both in Australia and overseas.

To learn more, please visit: www.wellnexlife.com.au/

Wellnex Life Limited

Building 2, Level 3, Suite 69, 574 Plummer Street, Port Melbourne VIC Australia
info@wellnexlife.com.au Phone: +61 3 8399 9419